On Wednesday, Shares of 3D Systems Corporation (NYSE:DDD), lost -4.40% to $8.70.
3D Systems (DDD) declared that it plans to present at the 18th annual Needham Growth Conference at The New York Palace Hotel in New York, NY on Tuesday, January 12, 2016 at 10:00 AM ET.
3D Systems Corporation, through its auxiliaries, operates as a provider of 3D printing centric design-to-manufacturing solutions in the Americas, Germany, and the Asia-Pacific, in addition to other European, the Middle East, and African countries.
Shares of NVIDIA Corporation (NASDAQ:NVDA), declined -0.86% to $33.39, during its last trading session.
NVIDIA will present at the following conference for the financial community:
- P. Morgan 14th Annual Tech Forum at the 2016 International CES
Wednesday, Jan. 6, 7:50 a.m. Pacific time
Bellagio Hotel, Las Vegas
NVIDIA Corporation operates as a visual computing company in the United States, Taiwan, China, and the rest of Asia Pacific, Europe, and other Americas. The company operates through two segments, GPU and Tegra Processors.
Finally, Merck & Co., Inc. (NYSE:MRK), ended its last trade with -0.17% loss, and closed at $53.25.
Merck (MRK), known as MSD outside the United States and Canada, declared that the application for Emergency Use Assessment and Listing (EUAL) for the company’s investigational Ebola Zaire vaccine, V920 (rVSV∆G-ZEBOV-GP, live attenuated), has been accepted for review by the World Health Organization (WHO).
According to the WHO, the EUAL process is designed to expedite the availability of vaccines needed for public health emergencies such as another outbreak of Ebola. The procedure is intended to assist United Nations’ procurement agencies and Member States on the acceptability of using a vaccine candidate in an emergency-use setting. EUAL designation is not prequalification by WHO, but rather is a special procedure implemented when there is an outbreak of a disease with high rates of morbidity and/or mortality and a lack of treatment and/or prevention options. In such instances, WHO may recommend making a vaccine available for a limited time, while further clinical trial data are being gathered for formal regulatory agency review by a national regulatory authority.
“This application to the WHO is an important step toward enabling V920 to be used if a public health emergency of international concern were to be declared for the Ebola Zaire species before licensure of the vaccine candidate,” said Paula Annunziato, M.D., vice president for clinical research, Merck Research Laboratories.
The decision to grant V920 EUAL status will be based on data regarding quality, safety, and efficacy/effectiveness; in addition to a risk/benefit analysis for emergency use. While EUAL designation allows for emergency use, the vaccine remains investigational and has not yet been licensed for commercial distribution.
Merck & Co., Inc. provides health care solutions worldwide. The company offer therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal infections, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, male pattern hair loss, and fertility diseases.
